市場調査レポート

商品コード

1453996

注射用細胞毒性薬の2030年までの市場予測：薬剤タイプ別、流通チャネル別、用途別、地域別の世界分析

Injectable Cytotoxic Drugs Market Forecasts to 2030 - Global Analysis By Drug Type, Distribution Channel, Application, and By Geography

出版日: 2024年03月03日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 652,131円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 824,985円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 997,839円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,178,550円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、注射用細胞毒性薬の世界市場は2023年に189億米ドルを占め、予測期間中にCAGR 7.4％で成長し、2030年には311億米ドルに達する見込みです。

注射用細胞毒性薬とは、急速に分裂するがん細胞を標的とし、破壊することで様々ながんを治療するために注射によって投与される薬剤のことです。これらの薬剤は、細胞分裂プロセスの阻害、細胞死の誘発、腫瘍増殖の抑制によって作用します。しばしば化学療法レジメンに使用され、メトトレキサート、ドキソルビシン、ビンクリスチンなどの薬剤が含まれます。その副作用にもかかわらず、注射用細胞毒性薬はがん治療において極めて重要であり、しばしば単独で、あるいは他の治療法と組み合わせて使用され、腫瘍を縮小させ、転移を予防し、患者の全生存率を向上させる。

ヘルスケア支出の増加

ヘルスケアの予算が拡大するにつれ、注射による細胞毒性薬を含む先進的ながん治療へのアクセスも向上しています。この支出の増加により、ヘルスケアシステムはがんと診断された患者に幅広い治療オプションを調達し提供することができます。さらに、ヘルスケア施設は注射用細胞毒性薬剤の保管、投与、管理に対応するための設備が整っているため、がん治療レジメンでの使用がさらに容易になり、この市場をさらに後押ししています。

高い開発コスト

新しい細胞毒性薬の開発には、大規模な前臨床試験、臨床試験、規制当局の承認が必要であり、プロセスの各段階で多額の費用が発生するため、製薬企業にとっては大きな財務的負担となります。さらに、米国のFDAや欧州のEMAのような規制当局からの承認取得や規制要件への対応が開発コストに拍車をかけ、市場開拓の足かせとなっています。

医薬品開発の進歩

ドラッグ製剤技術の進歩により、薬剤デリバリーと組織浸透を改善する、より安定した生物学的利用能の高い細胞毒性薬製剤が開発されています。これらの進歩は、創薬、製剤化、デリバリーの様々な側面を包含し、より安全で有効な細胞毒性療法の開発に貢献しています。さらに、これらのアプローチにより、研究者はがん細胞に対する選択性と効力が強化された化合物を同定できるようになると同時に、標的外への影響を最小限に抑えることができるようになり、この市場をさらに推進しています。

副作用と毒性

これらの薬剤は、急速に分裂するがん細胞を標的とする点では効果的であるが、患者のQOLや治療のアドヒアランスに影響を及ぼす副作用を引き起こすことが多いです。注射用細胞毒性薬の一般的な副作用には、吐き気、嘔吐、脱毛、疲労、免疫抑制などがあります。さらに、患者は、二次がんや臓器障害など、細胞毒性薬剤への曝露による長期的な合併症を発症する可能性もあり、これがこの市場規模の妨げとなっています。

COVID-19の影響

COVID-19パンデミックは注射用細胞毒性薬市場にいくつかの悪影響を与えました。世界のヘルスケアシステムの混乱は、がん検診、診断、治療の遅れにつながり、患者数の減少をもたらしました。さらに、封鎖、旅行制限、サプライチェーンの混乱から生じる物流の課題が、注射用細胞毒性薬の生産、流通、デリバリーを妨げています。このことは、特に資源が限られた環境において、注射用細胞毒性薬への患者のアクセスにさらに影響を与え、この市場を著しく阻害しています。

予測期間中、ビンカアルカロイドセグメントが最大となる見込み

ビンカアルカロイドセグメントは、がん治療における極めて重要な役割のため、最大のシェアを占めると推定されます。これらの薬剤は、微小管の形成を阻害することにより、細胞分裂を阻害し、急速に分裂するがん細胞にアポトーシスを誘導します。さらに、現在進行中の研究開発は、副作用を最小限に抑えながらビンカアルカロイドの治療効果を最適化することを目的としており、それによってこのセグメントの拡大を後押ししています。

多発性硬化症分野は予測期間中に最も高いCAGRが見込まれる

多発性硬化症分野は、その著しい成長と技術革新により、予測期間中のCAGRが最も高くなると予測されます。インターフェロンβ1a薬とインターフェロンβ1b薬は、免疫系の反応を調整し、MS患者の炎症と再発の頻度を減らすのに役立ちます。さらに、特定の免疫経路を標的とするモノクローナル抗体などの新たな治療薬が、MS患者の治療選択肢を広げつつあり、この分野の成長を牽引しています。

最大のシェアを占める地域

北米は、がんや多発性硬化症などの自己免疫疾患の有病率が高いため、この地域全体で注射用細胞毒性薬に対する大きな需要があります。この地域は、整備されたヘルスケア・インフラ、高度な医療施設、高水準の医療支出の恩恵を受けています。さらに、有利な償還政策と保険適用が、患者がこれらの必須医薬品を入手するのに貢献しており、この地域の拡大を後押ししています。

CAGRが最も高い地域：

欧州は、強力な製薬産業、最先端の研究、強固なヘルスケアインフラを有することから、予測期間中に最も高いCAGRを記録すると予想されます。欧州では、学術界、産業界、規制当局の協力体制がイノベーションを促進し、研究成果の臨床応用を加速させています。さらに、欧州では新しいドラッグデリバリー技術が採用され、注射用細胞毒性薬の治療効果と安全性プロファイルが向上しており、これがこの地域をさらに牽引しています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレーヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第9章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第10章企業プロファイル

Merck & Co. Inc.
Pfizer, Inc.
F. Hoffmann-La Roche Ltd.
Amgen, Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Sanofi
Johnson and Johnson Services Inc.
Abbie Inc
Novartis AG

図表

List of Tables

Table 1 Global Injectable Cytotoxic Drugs Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Injectable Cytotoxic Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
Table 3 Global Injectable Cytotoxic Drugs Market Outlook, By Vinca Alkaloids (2021-2030) ($MN)
Table 4 Global Injectable Cytotoxic Drugs Market Outlook, By Anthracyclines (2021-2030) ($MN)
Table 5 Global Injectable Cytotoxic Drugs Market Outlook, By Alkylating Agents (2021-2030) ($MN)
Table 6 Global Injectable Cytotoxic Drugs Market Outlook, By Taxanes (2021-2030) ($MN)
Table 7 Global Injectable Cytotoxic Drugs Market Outlook, By Antimetabolites (2021-2030) ($MN)
Table 8 Global Injectable Cytotoxic Drugs Market Outlook, By Platinum Compounds (2021-2030) ($MN)
Table 9 Global Injectable Cytotoxic Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 10 Global Injectable Cytotoxic Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 11 Global Injectable Cytotoxic Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 12 Global Injectable Cytotoxic Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 13 Global Injectable Cytotoxic Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 14 Global Injectable Cytotoxic Drugs Market Outlook, By Specialty Cancer Centers (2021-2030) ($MN)
Table 15 Global Injectable Cytotoxic Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 16 Global Injectable Cytotoxic Drugs Market Outlook, By Application (2021-2030) ($MN)
Table 17 Global Injectable Cytotoxic Drugs Market Outlook, By Oncology (2021-2030) ($MN)
Table 18 Global Injectable Cytotoxic Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 19 Global Injectable Cytotoxic Drugs Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
Table 20 Global Injectable Cytotoxic Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
Table 21 North America Injectable Cytotoxic Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 22 North America Injectable Cytotoxic Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
Table 23 North America Injectable Cytotoxic Drugs Market Outlook, By Vinca Alkaloids (2021-2030) ($MN)
Table 24 North America Injectable Cytotoxic Drugs Market Outlook, By Anthracyclines (2021-2030) ($MN)
Table 25 North America Injectable Cytotoxic Drugs Market Outlook, By Alkylating Agents (2021-2030) ($MN)
Table 26 North America Injectable Cytotoxic Drugs Market Outlook, By Taxanes (2021-2030) ($MN)
Table 27 North America Injectable Cytotoxic Drugs Market Outlook, By Antimetabolites (2021-2030) ($MN)
Table 28 North America Injectable Cytotoxic Drugs Market Outlook, By Platinum Compounds (2021-2030) ($MN)
Table 29 North America Injectable Cytotoxic Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 30 North America Injectable Cytotoxic Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 31 North America Injectable Cytotoxic Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 32 North America Injectable Cytotoxic Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 33 North America Injectable Cytotoxic Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 34 North America Injectable Cytotoxic Drugs Market Outlook, By Specialty Cancer Centers (2021-2030) ($MN)
Table 35 North America Injectable Cytotoxic Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 36 North America Injectable Cytotoxic Drugs Market Outlook, By Application (2021-2030) ($MN)
Table 37 North America Injectable Cytotoxic Drugs Market Outlook, By Oncology (2021-2030) ($MN)
Table 38 North America Injectable Cytotoxic Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 39 North America Injectable Cytotoxic Drugs Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
Table 40 North America Injectable Cytotoxic Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
Table 41 Europe Injectable Cytotoxic Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 42 Europe Injectable Cytotoxic Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
Table 43 Europe Injectable Cytotoxic Drugs Market Outlook, By Vinca Alkaloids (2021-2030) ($MN)
Table 44 Europe Injectable Cytotoxic Drugs Market Outlook, By Anthracyclines (2021-2030) ($MN)
Table 45 Europe Injectable Cytotoxic Drugs Market Outlook, By Alkylating Agents (2021-2030) ($MN)
Table 46 Europe Injectable Cytotoxic Drugs Market Outlook, By Taxanes (2021-2030) ($MN)
Table 47 Europe Injectable Cytotoxic Drugs Market Outlook, By Antimetabolites (2021-2030) ($MN)
Table 48 Europe Injectable Cytotoxic Drugs Market Outlook, By Platinum Compounds (2021-2030) ($MN)
Table 49 Europe Injectable Cytotoxic Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 50 Europe Injectable Cytotoxic Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 51 Europe Injectable Cytotoxic Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 52 Europe Injectable Cytotoxic Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 53 Europe Injectable Cytotoxic Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 54 Europe Injectable Cytotoxic Drugs Market Outlook, By Specialty Cancer Centers (2021-2030) ($MN)
Table 55 Europe Injectable Cytotoxic Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 56 Europe Injectable Cytotoxic Drugs Market Outlook, By Application (2021-2030) ($MN)
Table 57 Europe Injectable Cytotoxic Drugs Market Outlook, By Oncology (2021-2030) ($MN)
Table 58 Europe Injectable Cytotoxic Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 59 Europe Injectable Cytotoxic Drugs Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
Table 60 Europe Injectable Cytotoxic Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
Table 61 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 62 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
Table 63 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Vinca Alkaloids (2021-2030) ($MN)
Table 64 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Anthracyclines (2021-2030) ($MN)
Table 65 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Alkylating Agents (2021-2030) ($MN)
Table 66 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Taxanes (2021-2030) ($MN)
Table 67 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Antimetabolites (2021-2030) ($MN)
Table 68 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Platinum Compounds (2021-2030) ($MN)
Table 69 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 70 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 71 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 72 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 73 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 74 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Specialty Cancer Centers (2021-2030) ($MN)
Table 75 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 76 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Application (2021-2030) ($MN)
Table 77 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Oncology (2021-2030) ($MN)
Table 78 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 79 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
Table 80 Asia Pacific Injectable Cytotoxic Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
Table 81 South America Injectable Cytotoxic Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 82 South America Injectable Cytotoxic Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
Table 83 South America Injectable Cytotoxic Drugs Market Outlook, By Vinca Alkaloids (2021-2030) ($MN)
Table 84 South America Injectable Cytotoxic Drugs Market Outlook, By Anthracyclines (2021-2030) ($MN)
Table 85 South America Injectable Cytotoxic Drugs Market Outlook, By Alkylating Agents (2021-2030) ($MN)
Table 86 South America Injectable Cytotoxic Drugs Market Outlook, By Taxanes (2021-2030) ($MN)
Table 87 South America Injectable Cytotoxic Drugs Market Outlook, By Antimetabolites (2021-2030) ($MN)
Table 88 South America Injectable Cytotoxic Drugs Market Outlook, By Platinum Compounds (2021-2030) ($MN)
Table 89 South America Injectable Cytotoxic Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 90 South America Injectable Cytotoxic Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 91 South America Injectable Cytotoxic Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 92 South America Injectable Cytotoxic Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 93 South America Injectable Cytotoxic Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 94 South America Injectable Cytotoxic Drugs Market Outlook, By Specialty Cancer Centers (2021-2030) ($MN)
Table 95 South America Injectable Cytotoxic Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 96 South America Injectable Cytotoxic Drugs Market Outlook, By Application (2021-2030) ($MN)
Table 97 South America Injectable Cytotoxic Drugs Market Outlook, By Oncology (2021-2030) ($MN)
Table 98 South America Injectable Cytotoxic Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 99 South America Injectable Cytotoxic Drugs Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
Table 100 South America Injectable Cytotoxic Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
Table 101 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Country (2021-2030) ($MN)
Table 102 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
Table 103 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Vinca Alkaloids (2021-2030) ($MN)
Table 104 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Anthracyclines (2021-2030) ($MN)
Table 105 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Alkylating Agents (2021-2030) ($MN)
Table 106 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Taxanes (2021-2030) ($MN)
Table 107 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Antimetabolites (2021-2030) ($MN)
Table 108 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Platinum Compounds (2021-2030) ($MN)
Table 109 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
Table 110 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 111 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 112 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 113 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 114 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Specialty Cancer Centers (2021-2030) ($MN)
Table 115 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
Table 116 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Application (2021-2030) ($MN)
Table 117 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Oncology (2021-2030) ($MN)
Table 118 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 119 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
Table 120 Middle East & Africa Injectable Cytotoxic Drugs Market Outlook, By Other Applications (2021-2030) ($MN)

Product Code: SMRC25548

According to Stratistics MRC, the Global Injectable Cytotoxic Drugs Market is accounted for $18.9 billion in 2023 and is expected to reach $31.1 billion by 2030 growing at a CAGR of 7.4% during the forecast period. Injectable cytotoxic drugs refer to medications administered via injection to treat various cancers by targeting and destroying rapidly dividing cancer cells. These drugs work by interfering with cell division processes, inducing cell death, or inhibiting tumor growth. Often used in chemotherapy regimens, they include agents like methotrexate, doxorubicin, and vincristine. Despite their side effects, injectable cytotoxic drugs are crucial in cancer treatment, often used alone or in combination with other therapies to shrink tumors, prevent metastasis, and improve patients' overall survival rates.

Market Dynamics:

Driver:

Increasing healthcare expenditure

As healthcare budgets expand, there's greater accessibility to advanced cancer treatments, including cytotoxic drugs administered via injection. This increased spending enables healthcare systems to procure and offer a wider range of treatment options to patients diagnosed with cancer. Moreover, healthcare facilities are better equipped to handle the storage, administration, and management of injectable cytotoxic drugs, further facilitating their use in cancer treatment regimens and propelling this market further.

Restraint:

High development costs

Developing a new cytotoxic drug involves extensive preclinical studies, clinical trials, and regulatory approvals, which incur significant expenses at each stage of the process and contribute to substantial financial burdens for pharmaceutical companies. Moreover, navigating regulatory requirements and obtaining approvals from regulatory agencies such as the FDA in the United States and the EMA in Europe adds to the development costs, thereby gradually impedes this market growth.

Opportunity:

Advancements in drug development

Advancements in drug formulation technologies have led to the development of more stable, bioavailable cytotoxic drug formulations that improve drug delivery and tissue penetration. These advancements encompass various aspects of drug discovery, formulation, and delivery, contributing to the development of safer, more efficacious cytotoxic therapies. Moreover, these approaches enable researchers to identify compounds with enhanced selectivity and potency against cancer cells while minimizing off-target effects, propelling this market further.

Threat:

Side effects and toxicity

These medications, while effective in targeting rapidly dividing cancer cells, often lead to adverse effects that impact patients' quality of life and treatment adherence. Common side effects of injectable cytotoxic drugs include nausea, vomiting, hair loss, fatigue, and immunosuppression. Moreover, patients may also develop long-term complications from cytotoxic drug exposure, including secondary cancers and organ damage, which hinder this market size.

Covid-19 Impact

The COVID-19 pandemic has had several negative impacts on the injectable cytotoxic drug market. Disruptions in healthcare systems worldwide have led to delays in cancer screenings, diagnoses, and treatments, resulting in a reduction in the number of patients. Furthermore, logistical challenges arising from lockdowns, travel restrictions, and supply chain disruptions have hampered the production, distribution, and delivery of injectable cytotoxic drugs. This has further impacted patient access to injectable cytotoxic drugs, particularly in resource-limited settings, which significantly hinders this market.

The vinca alkaloids segment is expected to be the largest during the forecast period

The vinca alkaloids segment is estimated to hold the largest share, due to its pivotal role in cancer treatment. These drugs work by disrupting microtubule formation, thereby inhibiting cell division and inducing apoptosis in rapidly dividing cancer cells. Additionally, ongoing research and development efforts aim at optimizing Vinca alkaloids' therapeutic benefits while minimizing adverse effects, thereby boosting this segment's expansion.

The multiple sclerosis segment is expected to have the highest CAGR during the forecast period

The multiple sclerosis segment is anticipated to have highest CAGR during the forecast period due to its significant growth and innovation. Interferon beta-1a and interferon beta-1b drugs help regulate the immune system's response, reducing inflammation and the frequency of relapses in MS patients. Moreover, emerging therapies, including monoclonal antibodies targeting specific immune pathways, are expanding treatment options for MS patients, which is driving this segment's growth.

Region with largest share:

North America commanded the largest market share during the extrapolated period, owing to the high prevalence of cancer and autoimmune diseases such as multiple sclerosis, there is a substantial demand for injectable cytotoxic drugs across the region. The region benefits from a well-established healthcare infrastructure, advanced medical facilities, and a high level of healthcare spending. Furthermore, favorable reimbursement policies and insurance coverage contribute to patients' access to these essential medications, propelling this region's expansion.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to the region's strong pharmaceutical industry, cutting-edge research, and robust healthcare infrastructure. Collaborative efforts between academia, industry, and regulatory agencies in Europe foster innovation and accelerate the translation of research findings into clinical practice. In addition, Europe has witnessed the adoption of novel drug delivery technologies, enhancing the therapeutic efficacy and safety profile of injectable cytotoxic drugs, which drives this region further.

Key players in the market

Some of the key players in the Injectable Cytotoxic Drugs Market include Merck & Co. Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Amgen, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi, Johnson and Johnson Services Inc. , Abbie Inc, Novartis AG.

Key Developments:

In February 2024, Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology.

In July 2023, DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide platform, announced that it has been acquired by Novartis.

Drug Types Covered:

Vinca Alkaloids
Anthracyclines
Alkylating Agents
Taxanes
Antimetabolites
Platinum Compounds
Other Drug Types

Distribution Channel Covered:

Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Specialty Cancer Centers
Other Distribution Channels

Applications Covered:

Oncology
Multiple Sclerosis
Rheumatoid Arthritis
Other Applications

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Injectable Cytotoxic Drugs Market, By Drug Type

5.1 Introduction
5.2 Vinca Alkaloids
5.3 Anthracyclines
5.4 Alkylating Agents
5.5 Taxanes
5.6 Antimetabolites
5.7 Platinum Compounds
5.8 Other Drug Types

6 Global Injectable Cytotoxic Drugs Market, By Distribution Channel

6.1 Introduction
6.2 Retail Pharmacies
6.3 Online Pharmacies
6.4 Hospital Pharmacies
6.5 Specialty Cancer Centers
6.6 Other Distribution Channels

7 Global Injectable Cytotoxic Drugs Market, By Application

7.1 Introduction
7.2 Oncology
7.3 Multiple Sclerosis
7.4 Rheumatoid Arthritis
7.5 Other Applications

8 Global Injectable Cytotoxic Drugs Market, By Geography

8.1 Introduction
8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling

10.1 Merck & Co. Inc.
10.2 Pfizer, Inc.
10.3 F. Hoffmann-La Roche Ltd.
10.4 Amgen, Inc.
10.5 Bristol-Myers Squibb Company
10.6 Eli Lilly and Company
10.7 Sanofi
10.8 Johnson and Johnson Services Inc.
10.9 Abbie Inc
10.10 Novartis AG

注射用細胞毒性薬の2030年までの市場予測： 薬剤タイプ別、流通チャネル別、用途別、地域別の世界分析

Injectable Cytotoxic Drugs Market Forecasts to 2030 - Global Analysis By Drug Type, Distribution Channel, Application, and By Geography

最大のシェアを占める地域

CAGRが最も高い地域：

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界の注射用細胞毒性薬市場：薬剤タイプ別

第6章 世界の注射用細胞毒性薬市場：流通チャネル別

第7章 世界の注射用細胞毒性薬市場：用途別

第8章 世界の注射用細胞毒性薬市場：地域別

第9章 主な発展

第10章 企業プロファイル